You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVinorelbine
Accession NumberDB00361  (APRD00101)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionVinorelbine (Navelbine®) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer. [Wikipedia]
Structure
Thumb
Synonyms
5'-Noranhydrovinblastine
Nor-5'-anhydrovinblastine
Vinorelbin
Vinorelbina
Vinorelbine
Vinorelbinum
External Identifiers
  • KW 2307 base
  • KW-2307
  • UNII-253GQW851Q
  • UNII-Q6C979R91Y
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aj-vinorelbinesolution10 mgintravenousAgila Jamp Canada IncNot applicableNot applicableCanada
Navelbineinjection10 mg/mLintravenousPierre Fabre Pharmaceuticals, Inc.2005-11-15Not applicableUs
Navelbinesolution10 mgintravenousPierre Fabre Pharma Canada Inc1994-12-312012-10-01Canada
Vinorelbine Injectionsolution10 mgintravenousFresenius Kabi Canada Ltd2009-03-31Not applicableCanada
Vinorelbine Injection, USPsolution10 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Vinorelbine Injection, USPsolution10 mgintravenousGeneric Medical Partners IncNot applicableNot applicableCanada
Vinorelbine Tartrate for Injectionsolution10 mgintravenousHospira Healthcare Corporation2004-12-22Not applicableCanada
Vinorelbine Tartrate for Injectionsolution10 mgintravenousTeva Canada Limited2007-05-09Not applicableCanada
Vinorelbine Tartrate Injection USPsolution10 mgintravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vinorelbineinjection, solution10 mg/mLintravenousActavis Pharma, Inc.2009-09-14Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousMylan Institutional LLC2012-09-01Not applicableUs
Vinorelbineinjection, solution, concentrate10 mg/mLintravenousTeva Parenteral Medicines, Inc.2003-03-01Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousPfizer Laboratories Div Pfizer Inc.2012-09-01Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousMylan Institutional LLC2012-09-01Not applicableUs
Vinorelbineinjection, solution, concentrate50 mg/5mLintravenousTeva Parenteral Medicines, Inc.2003-03-01Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousMylan Institutional LLC2012-09-01Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousPfizer Laboratories Div Pfizer Inc.2012-09-01Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousHospira Worldwide, Inc.2005-06-02Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousSagent Pharmaceuticals2014-09-15Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousMylan Institutional LLC2012-09-01Not applicableUs
Vinorelbineinjection, solution10 mg/mLintravenousPfizer Laboratories Div Pfizer Inc.2012-09-01Not applicableUs
Vinorelbine Tartrateinjection, solution10 mg/mLintravenousWyeth Pharmaceuticals Company2008-02-13Not applicableUs
Vinorelbine Tartrateinjection, solution10 mg/mLintravenousSandoz Inc.2008-02-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BendarelbinBendalis
EberelbinEbewe
EunexonAC Farma
EurovinorelbinLapharm
FilcrinFilaxis
NavelbinPierre Fabre
NavildezCryopharma
NavinCancernova
Navirelmedac
NeocitecSandoz
RenovelMustafa Nevzat
RiborelbinRibosepharm
VilneDosa
VinelbineGP-Pharm
VinorayneHospira
VinorelEriochem
VinorgenBago
VinotelFresenius
ZinavinNovamed
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Vinorelbine Ditartrate
ThumbNot applicableDBSALT001060
Vinorelbine Tartrate
Thumb
  • InChI Key: CILBMBUYJCWATM-KRQCOKQWSA-N
  • Monoisotopic Mass: 1078.427040572
  • Average Mass: 1079.1059
DBSALT000447
Categories
UNIIQ6C979R91Y
CAS number71486-22-1
WeightAverage: 778.9323
Monoisotopic: 778.394164724
Chemical FormulaC45H54N4O8
InChI KeyInChIKey=GBABOYUKABKIAF-GHYRFKGUSA-N
InChI
InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45+/m0/s1
IUPAC Name
methyl (1R,9R,10R,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(12S,14R)-16-ethyl-12-(methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.0¹,⁹.0²,⁷.0¹⁶,¹⁹]nonadeca-2,4,6,13-tetraene-10-carboxylate
SMILES
[H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@@](CC)([C@@H](OC(C)=O)[C@@]2(O)C(=O)OC)[C@@]13[H])[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as vinca alkaloids. These are alkaloids with a dimeric chemical structure composed of an indole nucleus (catharanthine), and a dihydroindole nucleus (vindoline), joined together.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassVinca alkaloids
Sub ClassNot Available
Direct ParentVinca alkaloids
Alternative Parents
Substituents
  • Vinca alkaloid skeleton
  • Catharanthine skeleton
  • Carbazole
  • Indole or derivatives
  • Indole
  • Dialkylarylamine
  • Anisole
  • Aralkylamine
  • Tetrahydropyridine
  • Alkyl aryl ether
  • Benzenoid
  • N-alkylpyrrolidine
  • Dicarboxylic acid or derivatives
  • Heteroaromatic compound
  • Acetate salt
  • Methyl ester
  • Tertiary alcohol
  • Pyrrolidine
  • Pyrrole
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of non-small-cell lung carcinoma.
PharmacodynamicsVinorelbine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vinorelbine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Mechanism of actionThe antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 25.4 to 40.1 L/kg
Protein binding~27%
MetabolismNot Available
Route of eliminationVinorelbine undergoes substantial hepatic elimination in humans, with large amounts recovered in feces after intravenous administration to humans.
Half life27.7-43.6 hours
Clearance
  • 0.97 – 1.26 L/hr/kg
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Vinorelbine Action PathwayDrug actionSMP00439
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.974
Blood Brain Barrier-0.8815
Caco-2 permeable+0.5602
P-glycoprotein substrateSubstrate0.9283
P-glycoprotein inhibitor IInhibitor0.7488
P-glycoprotein inhibitor IIInhibitor0.7388
Renal organic cation transporterNon-inhibitor0.6979
CYP450 2C9 substrateNon-substrate0.8513
CYP450 2D6 substrateSubstrate0.6471
CYP450 3A4 substrateSubstrate0.7247
CYP450 1A2 substrateNon-inhibitor0.8415
CYP450 2C9 inhibitorNon-inhibitor0.7863
CYP450 2D6 inhibitorNon-inhibitor0.8369
CYP450 2C19 inhibitorNon-inhibitor0.8381
CYP450 3A4 inhibitorNon-inhibitor0.8095
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6672
Ames testNon AMES toxic0.8064
CarcinogenicityNon-carcinogens0.9299
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8350 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9014
hERG inhibition (predictor II)Non-inhibitor0.5171
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pierre fabre medicament
  • Actavis totowa llc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Ebewe pharma ges mbh nfg kg
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous10 mg/mL
Injection, solution, concentrateintravenous10 mg/mL
Injection, solution, concentrateintravenous50 mg/5mL
Injection, solutionintravenous10 mg/mL
Solutionintravenous10 mg
Prices
Unit descriptionCostUnit
Navelbine 50 mg/5 ml vial42.0USD ml
Vinorelbine 50 mg/5 ml vial27.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP4.39ALOGPS
logP4.65ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.87ChemAxon
pKa (Strongest Basic)8.72ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area133.87 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity216.99 m3·mol-1ChemAxon
Polarizability84.7 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C: Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001 Nov;12(11):1643-9. [PubMed:11822766 ]
External Links
ATC CodesL01CA04
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (102 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of Vinorelbine can be decreased when combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Vinorelbine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Vinorelbine.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Vinorelbine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Vinorelbine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Vinorelbine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Vinorelbine.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Vinorelbine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Vinorelbine.
AmiodaroneThe metabolism of Vinorelbine can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Vinorelbine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Vinorelbine.
AprepitantThe serum concentration of Vinorelbine can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Vinorelbine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Vinorelbine.
ArtemetherThe metabolism of Vinorelbine can be decreased when combined with Artemether.
AtazanavirThe metabolism of Vinorelbine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Vinorelbine.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Vinorelbine.
AtomoxetineThe metabolism of Vinorelbine can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Vinorelbine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Vinorelbine.
BetaxololThe metabolism of Vinorelbine can be decreased when combined with Betaxolol.
BevacizumabBevacizumab may increase the cardiotoxic activities of Vinorelbine.
BexaroteneThe serum concentration of Vinorelbine can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Vinorelbine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Vinorelbine.
BortezomibThe metabolism of Vinorelbine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Vinorelbine can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Vinorelbine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vinorelbine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Vinorelbine.
BupropionThe metabolism of Vinorelbine can be decreased when combined with Bupropion.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Vinorelbine.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinorelbine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Vinorelbine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Vinorelbine.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Vinorelbine.
CarbamazepineThe metabolism of Vinorelbine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Vinorelbine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Vinorelbine.
CelecoxibThe metabolism of Vinorelbine can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Vinorelbine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Vinorelbine.
ChloroquineThe metabolism of Vinorelbine can be decreased when combined with Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Vinorelbine.
ChlorpromazineThe metabolism of Vinorelbine can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of Vinorelbine can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Vinorelbine.
CimetidineThe metabolism of Vinorelbine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Vinorelbine can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Vinorelbine.
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Vinorelbine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Vinorelbine.
CitalopramThe metabolism of Vinorelbine can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Vinorelbine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Vinorelbine.
ClemastineThe metabolism of Vinorelbine can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Vinorelbine.
ClobazamThe metabolism of Vinorelbine can be decreased when combined with Clobazam.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Vinorelbine.
ClomipramineThe metabolism of Vinorelbine can be decreased when combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Vinorelbine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Vinorelbine.
ClotrimazoleThe metabolism of Vinorelbine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Clozapine.
ClozapineThe metabolism of Vinorelbine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Vinorelbine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Vinorelbine.
CocaineThe metabolism of Vinorelbine can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Vinorelbine.
ConivaptanThe serum concentration of Vinorelbine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Vinorelbine.
CrizotinibThe metabolism of Vinorelbine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Vinorelbine.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Vinorelbine.
CyclosporineThe metabolism of Vinorelbine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Vinorelbine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Vinorelbine.
DabrafenibThe serum concentration of Vinorelbine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Vinorelbine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Vinorelbine.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Vinorelbine.
DarifenacinThe metabolism of Vinorelbine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Vinorelbine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Vinorelbine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Vinorelbine.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Vinorelbine.
DeferasiroxThe serum concentration of Vinorelbine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Vinorelbine can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Vinorelbine.
DesipramineThe metabolism of Vinorelbine can be decreased when combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Vinorelbine.
DexamethasoneThe serum concentration of Vinorelbine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Vinorelbine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Vinorelbine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Vinorelbine.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Vinorelbine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Vinorelbine.
DigoxinDigoxin may decrease the cardiotoxic activities of Vinorelbine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Vinorelbine.
DihydroergotamineThe metabolism of Vinorelbine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Vinorelbine.
DiltiazemThe metabolism of Vinorelbine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Vinorelbine.
DiphenhydramineThe metabolism of Vinorelbine can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Vinorelbine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Vinorelbine.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Vinorelbine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Vinorelbine.
DoxycyclineThe metabolism of Vinorelbine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Vinorelbine can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of Vinorelbine can be decreased when combined with Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Vinorelbine.
EfavirenzThe serum concentration of Vinorelbine can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Vinorelbine.
EliglustatThe metabolism of Vinorelbine can be decreased when combined with Eliglustat.
EnzalutamideThe serum concentration of Vinorelbine can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Vinorelbine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Vinorelbine.
ErythromycinThe metabolism of Vinorelbine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Vinorelbine.
Eslicarbazepine acetateThe serum concentration of Vinorelbine can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Vinorelbine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Vinorelbine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Vinorelbine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Vinorelbine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Vinorelbine.
EtravirineThe serum concentration of Vinorelbine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Vinorelbine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Vinorelbine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Vinorelbine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Vinorelbine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Vinorelbine.
FingolimodVinorelbine may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe metabolism of Vinorelbine can be decreased when combined with Fluconazole.
FluoxetineThe metabolism of Vinorelbine can be decreased when combined with Fluoxetine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Vinorelbine.
FluvoxamineThe metabolism of Vinorelbine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Vinorelbine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Vinorelbine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Vinorelbine can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Vinorelbine can be increased when it is combined with Fusidic Acid.
GefitinibGefitinib may increase the neutropenic activities of Vinorelbine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Vinorelbine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Vinorelbine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Vinorelbine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Vinorelbine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Vinorelbine.
HaloperidolThe metabolism of Vinorelbine can be decreased when combined with Haloperidol.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Vinorelbine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Vinorelbine.
IdelalisibThe serum concentration of Vinorelbine can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Vinorelbine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Vinorelbine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Vinorelbine.
ImipramineThe metabolism of Vinorelbine can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Vinorelbine.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Vinorelbine.
IndinavirThe metabolism of Vinorelbine can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Vinorelbine.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Vinorelbine.
IsavuconazoniumThe metabolism of Vinorelbine can be decreased when combined with Isavuconazonium.
IsoniazidThe metabolism of Vinorelbine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Vinorelbine can be decreased when combined with Isradipine.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Vinorelbine.
IvacaftorThe serum concentration of Vinorelbine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Vinorelbine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Vinorelbine.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Vinorelbine.
KetoconazoleThe metabolism of Vinorelbine can be decreased when combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Vinorelbine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Vinorelbine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Vinorelbine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Vinorelbine.
LeflunomideThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Vinorelbine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Vinorelbine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Vinorelbine.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Vinorelbine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Vinorelbine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Vinorelbine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Vinorelbine.
LopinavirThe metabolism of Vinorelbine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Vinorelbine can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Vinorelbine.
LovastatinThe metabolism of Vinorelbine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Vinorelbine can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Vinorelbine can be decreased when combined with Lumefantrine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Vinorelbine.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Vinorelbine.
MethadoneThe metabolism of Vinorelbine can be decreased when combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Vinorelbine.
MethotrimeprazineThe metabolism of Vinorelbine can be decreased when combined with Methotrimeprazine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Vinorelbine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Vinorelbine.
MetoprololThe metabolism of Vinorelbine can be decreased when combined with Metoprolol.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Vinorelbine.
MifepristoneThe metabolism of Vinorelbine can be decreased when combined with Mifepristone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Vinorelbine.
MirabegronThe metabolism of Vinorelbine can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Vinorelbine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Vinorelbine.
ModafinilThe serum concentration of Vinorelbine can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Morphine can be increased when it is combined with Vinorelbine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Vinorelbine.
NadololThe serum concentration of Nadolol can be increased when it is combined with Vinorelbine.
NafcillinThe serum concentration of Vinorelbine can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Vinorelbine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Vinorelbine.
NatalizumabThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.
NefazodoneThe metabolism of Vinorelbine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Vinorelbine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Vinorelbine.
NetupitantThe serum concentration of Vinorelbine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Vinorelbine can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Vinorelbine.
NicardipineThe metabolism of Vinorelbine can be decreased when combined with Nicardipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Vinorelbine.
NilotinibThe metabolism of Vinorelbine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Vinorelbine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Vinorelbine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Vinorelbine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Vinorelbine.
OlaparibThe metabolism of Vinorelbine can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Vinorelbine.
OsimertinibThe serum concentration of Vinorelbine can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Vinorelbine.
PaclitaxelPaclitaxel may increase the neurotoxic activities of Vinorelbine.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Vinorelbine.
PalbociclibThe serum concentration of Vinorelbine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Vinorelbine.
PanobinostatThe metabolism of Vinorelbine can be decreased when combined with Panobinostat.
ParoxetineThe metabolism of Vinorelbine can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vinorelbine.
Peginterferon alfa-2bThe serum concentration of Vinorelbine can be decreased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Vinorelbine can be increased when combined with Pentobarbital.
PhenobarbitalThe metabolism of Vinorelbine can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Vinorelbine.
PhenytoinThe metabolism of Vinorelbine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Vinorelbine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Vinorelbine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Vinorelbine.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Vinorelbine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Vinorelbine.
PosaconazoleThe metabolism of Vinorelbine can be decreased when combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Vinorelbine.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Vinorelbine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Vinorelbine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Vinorelbine.
PrimidoneThe metabolism of Vinorelbine can be increased when combined with Primidone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Vinorelbine.
PromazineThe metabolism of Vinorelbine can be decreased when combined with Promazine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Vinorelbine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Vinorelbine.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Vinorelbine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Vinorelbine.
QuinidineThe metabolism of Vinorelbine can be decreased when combined with Quinidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Vinorelbine.
QuinineThe metabolism of Vinorelbine can be decreased when combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Rabies vaccine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Vinorelbine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Vinorelbine.
RanolazineThe metabolism of Vinorelbine can be decreased when combined with Ranolazine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Vinorelbine.
RifabutinThe metabolism of Vinorelbine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Vinorelbine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Vinorelbine.
RifapentineThe metabolism of Vinorelbine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Vinorelbine.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Vinorelbine.
RitonavirThe metabolism of Vinorelbine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Vinorelbine.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Vinorelbine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Vinorelbine.
RolapitantThe metabolism of Vinorelbine can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Vinorelbine.
RopiniroleThe metabolism of Vinorelbine can be decreased when combined with Ropinirole.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Vinorelbine.
SaquinavirThe metabolism of Vinorelbine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Vinorelbine.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Vinorelbine.
SertralineThe metabolism of Vinorelbine can be decreased when combined with Sertraline.
SildenafilThe metabolism of Vinorelbine can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vinorelbine.
SiltuximabThe serum concentration of Vinorelbine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Vinorelbine can be increased when it is combined with Simeprevir.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vinorelbine.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Vinorelbine.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Vinorelbine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Vinorelbine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Vinorelbine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Vinorelbine.
St. John's WortThe serum concentration of Vinorelbine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Vinorelbine can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Vinorelbine can be decreased when combined with Sulfisoxazole.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Vinorelbine.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Vinorelbine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Vinorelbine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Vinorelbine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Vinorelbine.
TelaprevirThe metabolism of Vinorelbine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Vinorelbine.
TelithromycinThe metabolism of Vinorelbine can be decreased when combined with Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Vinorelbine.
TerbinafineThe metabolism of Vinorelbine can be decreased when combined with Terbinafine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Vinorelbine.
ThioridazineThe metabolism of Vinorelbine can be decreased when combined with Thioridazine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Vinorelbine.
TiclopidineThe metabolism of Vinorelbine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Vinorelbine.
TipranavirThe metabolism of Vinorelbine can be decreased when combined with Tipranavir.
TocilizumabThe serum concentration of Vinorelbine can be decreased when it is combined with Tocilizumab.
TofacitinibVinorelbine may increase the immunosuppressive activities of Tofacitinib.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Vinorelbine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vinorelbine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Vinorelbine.
TranylcypromineThe metabolism of Vinorelbine can be decreased when combined with Tranylcypromine.
TrastuzumabTrastuzumab may increase the neutropenic activities of Vinorelbine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Vinorelbine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Vinorelbine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Vinorelbine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Vinorelbine.
VenlafaxineThe metabolism of Vinorelbine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Vinorelbine.
VerapamilThe metabolism of Vinorelbine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Vinorelbine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Vinorelbine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Vinorelbine can be decreased when combined with Voriconazole.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Vinorelbine.
ZiprasidoneThe metabolism of Vinorelbine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Ubiquitin protein ligase binding
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBB
Uniprot ID:
P07437
Molecular Weight:
49670.515 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT: Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998 Mar 1;55(5):635-48. [PubMed:9515574 ]
  4. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol. 1995 Apr;22(2 Suppl 5):66-70; discussion 70-1. [PubMed:7740336 ]
  5. Seve P, Dumontet C: [Class III beta tubulin expression in nonsmall cell lung cancer]. Rev Mal Respir. 2010 Apr;27(4):383-6. doi: 10.1016/j.rmr.2010.03.006. Epub 2010 Mar 25. [PubMed:20403547 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23